Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

Core Viewpoint - Sangamo Therapeutics reported a quarterly loss of $0.14 per share, which was worse than the Zacks Consensus Estimate of a loss of$0.11, marking an earnings surprise of -27.27% [1] - The company generated revenues of $6.44 million for the quarter, missing the consensus estimate by 29.77$0.48 million in the same quarter last year [2] Group 1: Financial Performance - The company has surpassed consensus EPS estimates only once in the last four quarters [2] - Sangamo shares have declined approximately 31.4% year-to-date, contrasting with the S&P 500's decline of -3.8% [3] Group 2: Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of$14.8 million, and for the current fiscal year, it is -$0.39 on revenues of$46.97 million [7] - The estimate revisions trend for Sangamo is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Group 3: Industry Context - The Medical - Biomedical and Genetics industry is ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]